Skip to content

Study · Animal study (in vivo) · mouse · 2016

8 results

Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.

Wang X, Ding Z, Yang F, Dai Y, Chen P, Theus S, Singh S, Budhiraja M, Mehta JL

Clinical science (London, England : 1979)26 Apr 2016Cited by 24 (Europe PMC)

PMID27129181 (opens in a new tab)DOI10.1042/cs20160061 (opens in a new tab)PepBankPUB-27129181
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide pre-treatment reduced myocardial infarct size.

    In plain wordsIn mice, liraglutide given before a heart attack-like injury reduced the size of the damaged heart area.

    Peptide
    Liraglutide
    Outcome
    DecreaseMyocardial infarct size
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Myocardial injury · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Pre-treatment with linagliptin or liraglutide reduced infarct size, protected cardiomyocytes from injury and preserved cardiac contractile function in a similar fashion.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide pre-treatment protected cardiomyocytes from injury.

    In plain wordsIn mice, liraglutide given before injury protected heart muscle cells from damage.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiomyocyte injury
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Myocardial injury · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Pre-treatment with linagliptin or liraglutide reduced infarct size, protected cardiomyocytes from injury and preserved cardiac contractile function in a similar fashion.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide pre-treatment preserved cardiac contractile function.

    In plain wordsIn mice, liraglutide given before injury helped keep the heart's pumping function.

    Peptide
    Liraglutide
    Outcome
    IncreaseCardiac contractile function
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Pre-treatment with linagliptin or liraglutide reduced infarct size, protected cardiomyocytes from injury and preserved cardiac contractile function in a similar fashion.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide suppressed reactive oxygen species generation.

    In plain wordsIn mice, liraglutide lowered the production of damaging reactive oxygen molecules in the injured heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseReactive oxygen species generation
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both linagliptin and liraglutide suppressed ROS generation, NADPH oxidase and proinflammatory signals, and reduced collagen deposition.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide suppressed NADPH oxidase signals.

    In plain wordsIn mice, liraglutide lowered NADPH oxidase signals in the injured heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseNADPH oxidase expression
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both linagliptin and liraglutide suppressed ROS generation, NADPH oxidase and proinflammatory signals, and reduced collagen deposition.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide suppressed proinflammatory signals.

    In plain wordsIn mice, liraglutide lowered inflammation signals in the injured heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseProinflammatory signals
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both linagliptin and liraglutide suppressed ROS generation, NADPH oxidase and proinflammatory signals, and reduced collagen deposition.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, liraglutide reduced collagen deposition.

    In plain wordsIn mice, liraglutide reduced scar-like collagen build-up in the injured heart.

    Peptide
    Liraglutide
    Outcome
    DecreaseCollagen deposition
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 5 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both linagliptin and liraglutide suppressed ROS generation, NADPH oxidase and proinflammatory signals, and reduced collagen deposition.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 08AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In mice with ischaemia-reperfusion, combined linagliptin and liraglutide had no significant additive effect over either drug alone.

    In plain wordsIn mice, giving linagliptin and liraglutide together did not add benefit beyond either drug alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdditive effect of linagliptin plus liraglutide
    Study

    mousen: not reported in source

    C57BL/6 mice with left coronary artery occlusion and reperfusion
    Comparator
    Either drug alone
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Addition of linagliptin or liraglutide had no significant additive effect above and beyond that of liraglutide and linagliptin given alone.
    1 context sentence
    Summary · context
    C57BL/6 mice were treated with vehicle, the DPP-4 inhibitor linagliptin, the GLP-1 activator liraglutide, or both agents together for 5 days, and then subjected to LCA occlusion (1 h) and reperfusion (3 h).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.